Wang H - Search Results

1

Active ingredients of traditional Chinese medicine for enhancing the effect of tumor immunotherapy.

Yang C, Li D, Ko CN, Wang K, Wang H. Yang C, et al. Among authors: wang h, wang k. Front Immunol. 2023 Mar 10;14:1133050. doi: 10.3389/fimmu.2023.1133050. eCollection 2023. Front Immunol. 2023. PMID: 36969211 Free PMC article. Review.

2

Previous Radiotherapy Increases the Efficacy of IL-2 in Malignant Pleural Effusion: Potential Evidence of a Radio-Memory Effect?

Chen D, Song X, Wang H, Gao Z, Meng W, Chen S, Ma Y, Wang Y, Li K, Yu J, Yue J. Chen D, et al. Among authors: wang h, wang y. Front Immunol. 2018 Dec 11;9:2916. doi: 10.3389/fimmu.2018.02916. eCollection 2018. Front Immunol. 2018. PMID: 30619280 Free PMC article.

3

Corrigendum: Previous Radiotherapy Increases the Efficacy of IL-2 in Malignant Pleural Effusion: Potential Evidence of a Radio-Memory Effect?

Chen D, Song X, Wang H, Gao Z, Meng W, Chen S, Ma Y, Wang Y, Li K, Yu J, Yue J. Chen D, et al. Among authors: wang h, wang y. Front Immunol. 2021 Mar 23;12:649620. doi: 10.3389/fimmu.2021.649620. eCollection 2021. Front Immunol. 2021. PMID: 33833763 Free PMC article.

4

A 5-Genomic Mutation Signature Can Predict the Survival for Patients With NSCLC Receiving Atezolizumab.

Lin J, Wang X, Zhang C, Bu S, Zhao C, Wang H. Lin J, et al. Among authors: wang x, wang h. Front Immunol. 2021 Jun 23;12:606027. doi: 10.3389/fimmu.2021.606027. eCollection 2021. Front Immunol. 2021. PMID: 34248926 Free PMC article. Clinical Trial.

5

Loss of heterozygosity related to TMB and TNB may predict PFS for patients with SCLC received the first line setting.

Zhang C, Wang K, Wang H. Zhang C, et al. Among authors: wang h, wang k. J Transl Med. 2021 Sep 8;19(1):385. doi: 10.1186/s12967-021-03019-6. J Transl Med. 2021. PMID: 34496866 Free PMC article. No abstract available.

6

Glytabastan B, a coumestan isolated from Glycine tabacina, alleviated synovial inflammation, osteoclastogenesis and collagen-induced arthritis through inhibiting MAPK and PI3K/AKT pathways.

Tu Y, Tan L, Lu T, Wang K, Wang H, Han B, Zhao Y, Chen H, Li Y, Chen H, Chen M, He C. Tu Y, et al. Among authors: wang h, wang k. Biochem Pharmacol. 2022 Mar;197:114912. doi: 10.1016/j.bcp.2022.114912. Epub 2022 Jan 12. Biochem Pharmacol. 2022. PMID: 35032460

7

Role of the Epigenetic Modifier JMJD6 in Tumor Development and Regulation of Immune Response.

Wang K, Yang C, Li H, Liu X, Zheng M, Xuan Z, Mei Z, Wang H. Wang K, et al. Among authors: wang h. Front Immunol. 2022 Mar 14;13:859893. doi: 10.3389/fimmu.2022.859893. eCollection 2022. Front Immunol. 2022. PMID: 35359945 Free PMC article. Review.

8

Non-small-cell lung cancer patients harboring TP53/KRAS co-mutation could benefit from a PD-L1 inhibitor.

Zhang C, Wang K, Lin J, Wang H. Zhang C, et al. Among authors: wang h, wang k. Future Oncol. 2022 Sep;18(27):3031-3041. doi: 10.2217/fon-2022-0295. Epub 2022 Sep 6. Future Oncol. 2022. PMID: 36065989

9

Immunomodulatory role of metalloproteinase ADAM17 in tumor development.

Wang K, Xuan Z, Liu X, Zheng M, Yang C, Wang H. Wang K, et al. Among authors: wang h. Front Immunol. 2022 Nov 17;13:1059376. doi: 10.3389/fimmu.2022.1059376. eCollection 2022. Front Immunol. 2022. PMID: 36466812 Free PMC article. Review.

10

PD-L1: Biological mechanism, function, and immunotherapy in gastric cancer.

Zhang Y, Yang Y, Chen Y, Lin W, Chen X, Liu J, Huang Y, Wang H, Teng L. Zhang Y, et al. Among authors: wang h. Front Immunol. 2022 Nov 24;13:1060497. doi: 10.3389/fimmu.2022.1060497. eCollection 2022. Front Immunol. 2022. PMID: 36505487 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

151,249 results

Search Page

Filters